Asked by: Glyn Davies (Conservative - Montgomeryshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how many people were diagnosed with urinary incontinence in each clinical commissioning group area in each of the last five years; and what the cost was of treating that condition in each such area in each such year.
Answered by Jane Ellison
The Department does not hold information on the number of people admitted to hospital for urinary incontinence.
A count of finished admission episodes with a primary diagnosis of urinary incontinence, by clinical commissioning group of residence, 2010-11 to 2014-15 is provided in the attached table.
The costs to the National Health Service of treating people with urinary tract infections and urinary incontinence is not available centrally.
Such information as is available is from reference costs, which are the average unit costs of providing defined services to patients. Reference costs for acute care are published by Healthcare Resource Group (HRG), which are standard groupings of similar treatments that use similar resources. For example, costs relating to kidney or urinary tract interventions are assigned to the same HRGs.
Table: Estimated total costs of kidney or urinary tract interventions and urinary incontinence or other urinary problems reported by NHS trusts and foundation trusts, 2010-11 to 2014-15 (£ millions)
Kidney or urinary tract interventions | Urinary incontinence or other urinary problems | |
2010-11 | 370.5 | 28.2 |
2011-12 | 398.9 | 28.1 |
2012-13 | 432.4 | 27.8 |
2013-14 | 464.8 | 28.3 |
2014-15 | 506.5 | 27.6 |
Source: Reference costs, Department of Health
Asked by: Glyn Davies (Conservative - Montgomeryshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what estimate his Department has made of the number of people with (a) urinary incontinence and (b) faecal incontinence in England.
Answered by Jane Ellison
NHS England has advised that according to a survey conducted in 2008, there are over 14 million adults who have bladder control problems and 6.5 million with bowel control problems in the United Kingdom.
The Department does not collect information on the number of people living with urinary and faecal incontinence specific to Northern Ireland, Scotland and Wales. This is a matter for devolved administrations.
The Healthcare Quality and Improvement Partnership (2010) established that in order to achieve the best clinical outcomes, continence services have to be integrated across primary and secondary care and care home settings.
They also concluded that ‘there is an urgent need for improved and equitable practice for all people with bladder and bowel problems’ through the development of commissioning frameworks, evidence-based training for health professionals and patient empowerment to increase their expectations of cure.
Improving continence care provision through integrated services brings many benefits including:
- a better quality of life and more independence through finding solutions appropriate to individual needs;
- less reliance on pads and products by using alternative treatments;
- a reduction in admissions to hospitals and care homes;
- fewer complications, such as urinary tract infections, faecal impaction and skin breakdown; and
- a reduction in costs.
NHS England’s Excellence in Continence Care guidance provides a framework that enables commissioners to work in collaboration with providers and others to make a step change to address shortfalls so that safe, dignified, efficient and effective continence care is consistently provided.
This guidance is aimed at commissioners, providers, health and social care staff and as information for the public and has been produced in partnership with patient and public advocates, clinicians and partners from the third sector. The roles of everyone involved in the care of people with continence needs are made clear in the guidance and publication via a launch is planned for ‘Self Care Week’ beginning 16 November. The launch will both raise awareness and promote understanding.
In addition the National Institute for Health and Care Excellence has produced a range of guidance for clinicians to support them in the diagnosis, treatment care and support and people with continence problems e.g. Urinary incontinence in women (September 2013), Faecal incontinence in adults (June 2007), Urinary incontinence in neurological disease: assessment and management (August 2012) and Lower urinary tract symptoms in men: management (May 2010).
Asked by: Glyn Davies (Conservative - Montgomeryshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps his Department is taking to improve the quality of care provided for people with incontinence in the UK.
Answered by Jane Ellison
NHS England has advised that according to a survey conducted in 2008, there are over 14 million adults who have bladder control problems and 6.5 million with bowel control problems in the United Kingdom.
The Department does not collect information on the number of people living with urinary and faecal incontinence specific to Northern Ireland, Scotland and Wales. This is a matter for devolved administrations.
The Healthcare Quality and Improvement Partnership (2010) established that in order to achieve the best clinical outcomes, continence services have to be integrated across primary and secondary care and care home settings.
They also concluded that ‘there is an urgent need for improved and equitable practice for all people with bladder and bowel problems’ through the development of commissioning frameworks, evidence-based training for health professionals and patient empowerment to increase their expectations of cure.
Improving continence care provision through integrated services brings many benefits including:
- a better quality of life and more independence through finding solutions appropriate to individual needs;
- less reliance on pads and products by using alternative treatments;
- a reduction in admissions to hospitals and care homes;
- fewer complications, such as urinary tract infections, faecal impaction and skin breakdown; and
- a reduction in costs.
NHS England’s Excellence in Continence Care guidance provides a framework that enables commissioners to work in collaboration with providers and others to make a step change to address shortfalls so that safe, dignified, efficient and effective continence care is consistently provided.
This guidance is aimed at commissioners, providers, health and social care staff and as information for the public and has been produced in partnership with patient and public advocates, clinicians and partners from the third sector. The roles of everyone involved in the care of people with continence needs are made clear in the guidance and publication via a launch is planned for ‘Self Care Week’ beginning 16 November. The launch will both raise awareness and promote understanding.
In addition the National Institute for Health and Care Excellence has produced a range of guidance for clinicians to support them in the diagnosis, treatment care and support and people with continence problems e.g. Urinary incontinence in women (September 2013), Faecal incontinence in adults (June 2007), Urinary incontinence in neurological disease: assessment and management (August 2012) and Lower urinary tract symptoms in men: management (May 2010).
Asked by: Glyn Davies (Conservative - Montgomeryshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what progress his Department has made on raising awareness and promoting understanding of incontinence amongst (a) health and social care staff and (b) the general public; and if he will make a statement.
Answered by Jane Ellison
NHS England has advised that according to a survey conducted in 2008, there are over 14 million adults who have bladder control problems and 6.5 million with bowel control problems in the United Kingdom.
The Department does not collect information on the number of people living with urinary and faecal incontinence specific to Northern Ireland, Scotland and Wales. This is a matter for devolved administrations.
The Healthcare Quality and Improvement Partnership (2010) established that in order to achieve the best clinical outcomes, continence services have to be integrated across primary and secondary care and care home settings.
They also concluded that ‘there is an urgent need for improved and equitable practice for all people with bladder and bowel problems’ through the development of commissioning frameworks, evidence-based training for health professionals and patient empowerment to increase their expectations of cure.
Improving continence care provision through integrated services brings many benefits including:
- a better quality of life and more independence through finding solutions appropriate to individual needs;
- less reliance on pads and products by using alternative treatments;
- a reduction in admissions to hospitals and care homes;
- fewer complications, such as urinary tract infections, faecal impaction and skin breakdown; and
- a reduction in costs.
NHS England’s Excellence in Continence Care guidance provides a framework that enables commissioners to work in collaboration with providers and others to make a step change to address shortfalls so that safe, dignified, efficient and effective continence care is consistently provided.
This guidance is aimed at commissioners, providers, health and social care staff and as information for the public and has been produced in partnership with patient and public advocates, clinicians and partners from the third sector. The roles of everyone involved in the care of people with continence needs are made clear in the guidance and publication via a launch is planned for ‘Self Care Week’ beginning 16 November. The launch will both raise awareness and promote understanding.
In addition the National Institute for Health and Care Excellence has produced a range of guidance for clinicians to support them in the diagnosis, treatment care and support and people with continence problems e.g. Urinary incontinence in women (September 2013), Faecal incontinence in adults (June 2007), Urinary incontinence in neurological disease: assessment and management (August 2012) and Lower urinary tract symptoms in men: management (May 2010).
Asked by: Glyn Davies (Conservative - Montgomeryshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what estimate his Department has made of the number of people living with (a) urinary incontinence and (b) faecal incontinence in (i) Northern Ireland, (ii) Scotland and (iii) Wales.
Answered by Jane Ellison
NHS England has advised that according to a survey conducted in 2008, there are over 14 million adults who have bladder control problems and 6.5 million with bowel control problems in the United Kingdom.
The Department does not collect information on the number of people living with urinary and faecal incontinence specific to Northern Ireland, Scotland and Wales. This is a matter for devolved administrations.
The Healthcare Quality and Improvement Partnership (2010) established that in order to achieve the best clinical outcomes, continence services have to be integrated across primary and secondary care and care home settings.
They also concluded that ‘there is an urgent need for improved and equitable practice for all people with bladder and bowel problems’ through the development of commissioning frameworks, evidence-based training for health professionals and patient empowerment to increase their expectations of cure.
Improving continence care provision through integrated services brings many benefits including:
- a better quality of life and more independence through finding solutions appropriate to individual needs;
- less reliance on pads and products by using alternative treatments;
- a reduction in admissions to hospitals and care homes;
- fewer complications, such as urinary tract infections, faecal impaction and skin breakdown; and
- a reduction in costs.
NHS England’s Excellence in Continence Care guidance provides a framework that enables commissioners to work in collaboration with providers and others to make a step change to address shortfalls so that safe, dignified, efficient and effective continence care is consistently provided.
This guidance is aimed at commissioners, providers, health and social care staff and as information for the public and has been produced in partnership with patient and public advocates, clinicians and partners from the third sector. The roles of everyone involved in the care of people with continence needs are made clear in the guidance and publication via a launch is planned for ‘Self Care Week’ beginning 16 November. The launch will both raise awareness and promote understanding.
In addition the National Institute for Health and Care Excellence has produced a range of guidance for clinicians to support them in the diagnosis, treatment care and support and people with continence problems e.g. Urinary incontinence in women (September 2013), Faecal incontinence in adults (June 2007), Urinary incontinence in neurological disease: assessment and management (August 2012) and Lower urinary tract symptoms in men: management (May 2010).
Asked by: Glyn Davies (Conservative - Montgomeryshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what assessment his Department has made of the effectiveness of the Anti-PD-L1 drug in treating bladder cancer.
Answered by George Freeman
Two Anti-PD monoclonal antibody products are being evaluated in clinical trials for various cancers, including bladder cancer.
MPDL3280A, an anti-PD-L1 antibody made by Roche/Genentech, is undergoing a phase I trial (NCT01375842) in patients with locally advanced or metastatic solid tumours. The estimated study completion date is November 2016. The product is also being tested in a phase II trial in in patients with locally advanced or metastatic urothelial bladder cancer (NCT02108652). The estimated completion date for this Phase II trial is January 2016.
The second anti-PD antibody is Nivolumab produced by Bristol-Myers Squibb. Nivolumab on its own, or in combination with another monoclonal antibody ipilimumab (Yervoy®), is in a phase I/II trial in several cancers, including bladder cancer (NCT01928394). This trial is expected to be completed by March 2017.
No assessment of the data from any of these trials has been made to date.